tradingkey.logo

IGM Biosciences Inc <IGMS.OQ> expected to post a loss of 41 cents a share - Earnings Preview

ReutersMay 2, 2025 11:28 AM
  • IGM Biosciences Inc IGMS.OQ IGMS.O is expected to show a rise in quarterly revenue when it reports results on May 6 (estimated) for the period ending March 31 2025

  • The Mountain View California-based company is expected to report a 524.1% increase in revenue to $3.102 million from $497 thousand a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for IGM Biosciences Inc is for a loss of 41 cents per share.

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 5 "hold" and 2 "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for IGM Biosciences Inc is $2.00​, above​ its last closing price of $1.34. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.72

-0.74

-0.61

Beat

17.3

Sep. 30 2024

-0.81

-0.80

-1.01

Missed

-26.2

Jun. 30 2024

-0.02

-0.04

-0.79

Missed

-1,991.1​

Mar. 31 2024

-0.83

-0.83

-0.83

Met

0.2

​​Dec. 31 2023

-0.96

-1.03

-1.01

Beat

2.2

Sep. 30 2023

-1.18

-1.21

-1.04

Beat

14.3​

Jun. 30 2023

-1.44

-1.43

-1.43

Met

0.3

Mar. 31 2023

-1.34

-1.36

-1.33

Beat

2.5

This summary was machine generated May 2 at 11:28 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI